EUCTR2007-005670-31-AT进行中（未招募）不适用
A phase 2, multicenter, open-label, single arm, two-stage study to evaluate the efficacy and safety of CC-4047 (Pomalidomide) in patients with advanced soft tissue sarcomas who have relapsed or are refractory to systemic anticancer therapy
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 167
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •· Must understand and voluntarily sign an informed consent form
- •· Must be = 18 years of age at the time of consent
- •· Must be able to adhere to the study visit schedule and requirements of the protocol
- •· Must have histologically confirmed soft tissue sarcoma
- •· Must have locally recurrent, unresectable or metastatic soft tissue sarcoma, and
- •have failed or relapsed after a minimum of one and a maximum of 3 prior systemic
- •anticancer therapy regimens
- •- Prior treatment must not have included any anti-angiogenic therapy
- •- Prior treatment must have included both doxorubicin and ifosfamide
- •- Adjuvant therapy containing doxorubicin and/or ifosfamide will be considered as prior systemic anticancer therapy regimen if subject has relapsed within 12 months of the completion of the adjuvant therapy
- •· Must have measurable or evaluable disease determined as per RECIST criteria
- •· Must have documented disease progression (PD) determined as per RECIST
- •criteria within 3 months prior to study enrollment
- •· Must have an Eastern Cooperative Oncology Group (ECOG) performance status
- •score of 0 or 1
- •· Must have life expectancy of = 12 weeks
- •· A female of childbearing potential (FCBP) must agree to use two reliable forms
- •of contraception simultaneously or to practice complete abstinence from
- •heterosexual intercourse for at least 28 days before starting study drug, while
- •participating in the study and for at least 28 days after the treatment discontinuation visit. FCBP must agree to pregnancy testing (weekly for the 1st 28 days) and contraceptive counseling every 28 days during the study. FCBP must also refrain from donating blood and or eggs or ovum while participating in the study and for at least 28 days after the treatment discontinuation visit
- •· Males must agree to use a latex condom during any sexual contact with FCBP
- •while participating in this study and for at least 28 days following the treatment
- •discontinuation visit even if he has undergone a successful vasectomy. Males must
- •also agree to refrain from donating blood, semen, or sperm while participating in
- •this study and for at least 28 days after the treatment discontinuation visit
- •· Study subjects must agree to not share study drug with anyone during participation
- •in the study
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •· Any serious medical condition, laboratory abnormality, or psychiatric illness that
- •would prevent the study subject from signing the informed consent form
- •· Pregnant or lactating females
- •· Prior therapy with Thalidomide or Lenalidomide
- •· Prior use of any anti-angiogenic therapy
- •· Prior use of experimental/investigational drug therapy < 3 months prior to
- •treatment initiation
- •· Prior chemotherapy, biologic or immunotherapy < 3 weeks prior to treatment
- •· Prior radiotherapy < 3 weeks prior to treatment initiation
- •· Prior major surgery < 3 weeks prior to treatment initiation
- •· Known hypersensitivity to any IMiDs
- •· Unable to receive prophylactic anti-coagulation
- •· Any of the following laboratory values:
- •- Absolute neutrophil count (ANC) < 1.5 x 10^9 cells/L
- •- Platelet count < 100 x 10^9 cells/L
- •- Creatinine Clearance < 50 mL/min by Cockcroft-Gault formula
- •- Total bilirubin > 1.5 x the upper limit of normal (ULN) or > 2.0 x ULN in the
- •presence of demonstrable liver metastases
- •- Aspartate transaminase (serum glutamate oxaloacetic transaminase )(AST [SGOT]) and alanine transaminase (serum glutamate pyruvic transaminase)
- •(ALT [SGPT]) > 3.0 x ULN or > 5.0 x ULN in the presence of demonstrable liver metastases
- •· Active infection requiring systemic antibiotics
- •· Known HIV, hepatitis B virus (HBV) and/or
- •hepatitis C virus (HCV) infection
- •· Known active CNS metastases
- •· Any of following subtype of sarcomas:
- •- Osteosarcoma
- •- Chondrosarcoma
- •- Kaposi’s sarcoma associated with HIV
- •- Mesothelioma
- •· Prior history of malignancies, unless the study subject has been free of the disease
- •for 2 years. Exceptions include the following:
- •- Basal cell carcinoma of the skin
- •- Squamous cell carcinoma of the skin
- •- Carcinoma in situ of the cervix
- •- Carcinoma in situ of the breast
- •- Incidental histological finding of prostate cancer (Tumor Node Metastasis [TNM] stage of T1a or T1b)
研究者
相似试验
进行中（未招募）
不适用
A study evaluating novel BRAF inhibitor encorafenib (LGX818) when used as single agent in patients with advanced or metastatic BRAF V600 mutant non-small cell lung carcinoma.EUCTR2013-005014-34-ITOVARTIS FARMA S.p.A.58
进行中（未招募）
1 期
A phase II, multicentre, open-label, single arm, extension study of maintenancetreatment with subcutaneous homoharringtonine (HHT) as a single agent inpatients with chronic myeloid leukemia (CML) who received HHT in study HHT-CML/INTL/04.2 and have achieved a complete hematological response (CHR)or returned to chronic phase.Chronic myeloid leukemia (CML)EUCTR2005-000814-11-GBSTRAGEN France60
进行中（未招募）
1 期
The purpose of this study to evaluate how effective, safe and tolerable SOF/GS-5816 is when taken for 12 weeks by people infected with HCV and who are recent injection drug users. For the purpose of this study anyone who has injected drugs in the previous 24 weeks is considered to be a recent injection drug user.Chronic hepatitis C all genotypesMedDRA version: 18.1Level: PTClassification code 10019744Term: Hepatitis CSystem Organ Class: 10021881 - Infections and infestationsEUCTR2015-000178-36-GBniversity of New South Wales103
进行中（未招募）
1 期
A phase II, open-label, multi-centre, single-arm study, evaluating the efficacy of Glivec® plus Hydroxyurea (HU) in patients with progressive glioblastoma multiforme (GBM), receiving enzyme inducing anticonvulsant drugs (EIACDs).progressive glioblastoma multiforme (GBM) following failure of front-line therapy defined to include surgery, radiotherapy and exposure to temozolomide chemotherapy regimen.EUCTR2005-002603-16-DKovartis Pharma Services AG110
进行中（未招募）
不适用
A phase II, open-label, multi-centre, single-arm study, evaluating the efficacy of Glivec® plus Hydroxyurea (HU) in patients with progressive glioblastoma multiforme (GBM), not receiving enzyme inducing anticonvulsant drugs (EIACDs).EUCTR2005-002600-41-SEovartis Pharma Services AG110